State Street Corp Viking Therapeutics, Inc. Transaction History

State Street Corp

$2.8 Trillion
Q3 2025

A detailed history of State Street Corp transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 4,513,832 shares of VKTX stock, worth $180 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,513,832

Previous 3,775,691 19.55%

Holding current value

$180 Million

Previous $100 Million 15.22%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$23.09 - $42.09 $17 Million - $31.1 Million	738,141 Added 19.55%	4,513,832 $115 Million
Q2 2025 Aug 14, 2025	SELL	$19.98 - $29.49 $5.59 Million - $8.25 Million	-279,727 Reduced 6.9%	3,775,691 $100 Million
Q1 2025 May 15, 2025	SELL	$24.15 - $42.89 $21 Million - $37.3 Million	-870,072 Reduced 17.66%	4,055,418 $97.9 Million
Q4 2024 Feb 14, 2025	BUY	$38.28 - $78.03 $9.62 Million - $19.6 Million	251,423 Added 5.38%	4,925,490 $198 Million
Q3 2024 Nov 14, 2024	SELL	$49.84 - $70.47 $22.3 Million - $31.6 Million	-448,361 Reduced 8.75%	4,674,067 $296 Million

Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $85.1 Million - $144 Million	1,795,861 Added 53.99%	5,122,428 $272 Million
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $41.9 Million - $227 Million	-2,406,423 Reduced 41.98%	3,326,567 $273 Million
Q4 2023 Feb 14, 2024	SELL	$9.24 - $19.64 $6.27 Million - $13.3 Million	-678,072 Reduced 10.58%	5,732,990 $107 Million
Q3 2023 Nov 14, 2023	BUY	$10.92 - $16.0 $17.4 Million - $25.5 Million	1,591,686 Added 33.03%	6,411,062 $71 Million
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $6.85 Million - $11.4 Million	-461,568 Reduced 8.74%	4,819,376 $78.1 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $40.7 Million - $87.2 Million	5,034,102 Added 2039.4%	5,280,944 $87.9 Million
Q3 2022 Nov 15, 2022	SELL	$2.55 - $3.89 $36,210 - $55,238	-14,200 Reduced 5.44%	246,842 $671,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $3.15 $2.31 Million - $3.45 Million	-1,096,134 Reduced 80.77%	261,042 $754,000
Q1 2022 May 16, 2022	SELL	$3.0 - $4.88 $8.31 Million - $13.5 Million	-2,768,391 Reduced 67.1%	1,357,176 $4.07 Million
Q4 2021 Feb 14, 2022	BUY	$4.6 - $6.72 $383,253 - $559,883	83,316 Added 2.06%	4,125,567 $19 Million
Q3 2021 Nov 15, 2021	SELL	$5.58 - $7.04 $5.27 Million - $6.64 Million	-943,709 Reduced 18.93%	4,042,251 $25.4 Million
Q2 2021 Aug 16, 2021	SELL	$5.19 - $6.73 $9.33 Million - $12.1 Million	-1,798,484 Reduced 26.51%	4,985,960 $29.9 Million
Q1 2021 May 17, 2021	BUY	$5.74 - $9.67 $9.83 Million - $16.6 Million	1,711,888 Added 33.75%	6,784,444 $42.9 Million
Q4 2020 Feb 16, 2021	BUY	$5.3 - $6.71 $76,277 - $96,570	14,392 Added 0.28%	5,072,556 $28.6 Million
Q3 2020 Nov 10, 2020	BUY	$5.73 - $8.11 $4.48 Million - $6.34 Million	781,402 Added 18.27%	5,058,164 $29.4 Million
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $2.76 Million - $5.13 Million	634,812 Added 17.43%	4,276,762 $30.8 Million
Q1 2020 May 11, 2020	BUY	$3.45 - $7.95 $12.6 Million - $29 Million	3,641,950 New	3,641,950 $17 Million

Others Institutions Holding VKTX

# of Institutions

434

Shares Held

66.6M

Call Options Held

7.21M

Put Options Held

3.87M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.05B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Viking Therapeutics, Inc. Transaction History